AHA 2010: Sanofi-Aventis drops ischaemia gene therapy after Phase III failure
This article was originally published in Clinica
Executive Summary
A gene therapy developed by Sanofi-Aventis to treat ischaemia was unable to prevent amputations or death in a late-stage clinical trial.